Lamzede
February 16, 2023Filspari
February 17, 2023February 17, 2023 – Apellis Pharmaceuticals, Inc. a global biopharmaceutical company and leader in complement, has announced that FDA has approved SyfovreTM (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Syfovre is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide. GA is an advanced form of AMD. It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.
Syfovre is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. It is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation.
Most common adverse reactions are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.